The partnership with Skyhawk Therapeutics positions Ipsen at the forefront of RNA-based treatments for neurological conditions, a niche but rapidly growing area in healthcare. Given the focus on rare diseases, this collaboration could lead to high-value, differentiated products. The positive score reflects the potential for this partnership to enhance Ipsen's product pipeline and market position in the long term, although the immediate financial impact may be limited due to the early stages of development.